ProKidney completes de-SPAC merger; begins trading as PROK on Nasdaq

PROKIDNEY CORP.

Social Capital Suvretta Holdings Corp. III merged with ProKidney LP; renamed ProKidney Corp.
~22.8M public shares redeemed at ~$10.00 each, leaving ~$21.7M in trust post-closing.
Outstanding equity after close: 9.06M Class A shares from SPAC holders and 52.48M Class A shares from PIPE.
Class A ordinary shares began trading under ticker PROK on Nasdaq on July 12, 2022.
Lock-up restrictions range from 30 days to 4 years, with earn-out milestones at $12.50 and $15.00 per share.

item 1.01 item 2.01 item 9.01 item 5.02 item 4.01 item 3.02 item 3.03 item 5.01 item 5.03 item 5.06 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jennifer Fox

member of the board of directors

PROK · PROKIDNEY CORP.

Effective: 2022-07-11
Filed: July 15, 2022, 7:59 PM ET

On July 11, 2022, the New ProKidney board of directors appointed Jennifer Fox as a member of the board of directors

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer Fox was appointed as member of the board of directors at PROKIDNEY CORP..

Action: appointed
Role: member of the board of directors

Exact text from the filing

On July 11, 2022, the New ProKidney board of directors appointed Jennifer Fox as a member of the board of directors

View on SEC.gov

PROKIDNEY CORP. filing history →

Source: SEC EDGAR

accession 0001193125-22-195148

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.